For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use
Pancragen (Lys-Glu-Asp-Trp, KEDW) is the pancreas-targeted member of the Khavinson bioregulator family, making it uniquely distinctive in this series: it has published indexed human clinical data. A 2011 study in 33 elderly type 2 diabetes patients reported significant fasting glucose reduction, improved glucose tolerance, and reduced insulin resistance index, with no equivalent changes in untreated comparators. Rhesus monkey studies (2014, 2015) demonstrated glucose normalization and improved C-peptide dynamics comparable to glimepiride. Cell culture studies show activation of key pancreatic differentiation transcription factors. No randomized controlled trial has been published, and all human data originate from one institution. The glucose-lowering signal is real enough to warrant serious caution about combining Pancragen with existing antidiabetic medications without medical supervision.
The complete Pancragen profile includes all use cases with full evidence reviews, mechanism of action deep dive, safety analysis, evidence table, dosing guidance, and stack compatibility data.
For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use